Darbepoetin decreased transfusions and fatigue, but increased adverse effects in patients with chronic kidney disease, diabetes, and anemia
- How are patients with type 2 diabetes and renal disease monitored and managed? Insights from the observational OREDIA study. Penfornis, Alfred; Blicklé, Jean Frédéric; Fiquet, Béatrice; Quéré, Stéphane; Dejager, Sylvie // Vascular Health & Risk Management;2014, Vol. 10, p341
Background and aim: Chronic kidney disease (CKD) is frequent in type 2 diabetes mellitus (T2DM), and therapeutic management of diabetes is more challenging in patients with renal impairment (RI). The place of metformin is of particular interest since most scientific societies now recommend using...
- Efficacy and Safety of Sitagliptin Versus Glipizide in Patients With Type 2 Diabetes and Moderate-to-Severe Chronic Renal Insufficiency. FERREIRA, JUAN CAMILO ARJONA; MARRE, MICHEL; BARZILAI, NIR; HUA GUO; GOLM, GREGORY T.; SISK, CHRISTINE MCCRARY; KAUFMAN, KEITH D.; GOLDSTEIN, BARRY J. // Diabetes Care;May2013, Vol. 36 Issue 5, p1067
OBJECTIVE--Patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease have d an increased risk of micro- and macrovascular disease, but limited options for antihyperglycemic therapy. We compared the efficacy and safety of sitagliptin with glipizide in patients with T2DM and...
- Uncontrolled Hypertension in Diabetic CKD Patients. STEIN, JILL // Renal & Urology News;Oct2012, Vol. 11 Issue 10, p30
The article focuses on the results of a study conducted by Robert Stellhorn and associates which reveal that the proportion of patients with type 2 diabetes with uncontrolled hypertension is higher compared to patients with chronic kidney disease (CKD) than those without CKD.
- Identified single-nucleotide polymorphisms and haplotypes at 16q22.1 increase diabetic nephropathy risk in Han Chinese population. Li-Na Liao; Ching-Chu Chen; Fang-Yang Wu; Cheng-Chieh Lin; Jen-Hao Hsiao; Chwen-Tzuei Chang; Kardia, Sharon L. R.; Tsai-Chung Li; Fuu-Jen Tsai // BMC Genetics;2014, Vol. 15 Issue 1, p1
Background Diabetic nephropathy (DN) has become one of the most common causes of end-stage renal disease (ESRD) in many countries, such as 44.5% in Taiwan. Previous studies have shown that there is a genetic component to ESRD. Studies attempting to determine which genetic variants are related to...
- Riser BP is Common in CKD Patients. // Renal & Urology News;Jul2012, Vol. 11 Issue 7, p11
The article reports on a study presented at the annual meeting of the American Society of Hypertension which shows that chronic kidney disease (CKD) and type 2 diabetes patients have higher risks of riser blood pressure (BP) pattern.
- Erythrocyte metformin levels in patients with type 2 diabetes and varying severity of chronic kidney disease. Briet, Claire; Saraval-Gross, Marie; Kajbaf, Farshad; Fournier, Albert; Hary, Lionel; Lalau, Jean-Daniel // Clinical Kidney Journal;Jan2012, Vol. 5 Issue 1, p65
No abstract available.
- Plasma Copeptin and Renal Outcomes in Patients With Type 2 Diabetes and Albuminuria. VELHO, GILBERTO; BOUBY, NADINE; HADJADJ, SAMY; MATALLAH, NADIA; MOHAMMEDI, KAMEL; FUMERON, FRÉDÉRIC; POTIER, LOUIS; BELLILI-MUNOZ, NAÏMA; TAVEAU, CHRISTOPHER; ALHENC-GELAS, FRANÇOIS; BANKIR, LISE; MARRE, MICHEL; ROUSSEL, RONAN // Diabetes Care;Nov2013, Vol. 36 Issue 11, p3639
OBJECTIVE-Plasma copeptin, a surrogate for vasopressin, was associated with albuminuria in population-based studies. These associations are consistent with the effect of vasopressin on albuminuria observed in humans and rodents. The objective of this study was to determine whether plasma...
- Strategies for insulin impairment. R.M.D. // Cortlandt Forum;2/25/96, Vol. 9 Issue 2, p124
Responds to queries on efficacy of prescribing hypoglycemic agents among non-insulin dependent diabetics. Insulin levels; Recommendations for alternative medication regimen including exercise and proper diet.
- Monotherapy Clinical Trials. // Pharmacy Today;Sep2011 Supplement, p4
The article focuses on the two double-blind, placebo-controlled studies involving 730 patients with type 2 diabetes which evaluate the efficacy and safety of the oral dipeptidyl peptidase-4 (DPP-4) inhibitor called Tradjenta.